ArticleEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)2026
Impact of anal precancer screening on patient-reported outcomes among men-who-have-sex-with-men living with HIV: a scoping review.
Article in European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Interest in human papillomavirus (HPV)-related anal cancer screening among high-risk groups like men-who-have-sex-with-men living with HIV (MSMLWH) is high. Yet, the psychosocial impact of screening is not yet clear. We reviewed literature on patient-reported outcomes (PROs) associated with anal precancer screening among MSMLWH to identify current research priorities. In this scoping review, inclusion criteria were peer-reviewed studies of any type published in English since 2000 reporting PROs after anal precancer screening in MSMLWH. A database search (MEDLINE, EMBASE, and APA PsycINFO) was conducted in December 2024. Data were extracted independently by two authors using a standardised form. Eleven papers (nine cohorts) met the inclusion criteria, mostly from high-income countries. Participants were generally over 40 and had lived with HIV for greater than or equal to 10 years. All were involved in anal precancer screening studies; none were part of routine screening programmes. Ethnicity data were inconsistently reported. Papers covered four PRO domains: health-related quality of life (HRQoL), psychological impact, experience of screening procedures, and physical health. Screening was well-tolerated with minimal psychological or HRQoL impact. Negative impact related to screening procedures did not persist beyond receiving results. Low levels of pain and discomfort (≤11%) were reported. Some reported increased cancer-related worry, especially when further examination was needed. Systematic collection of PROs in this context remains uncommon. Existing evidence suggests screening is generally well tolerated with minimal psychological burden, though some studies note psychosocial effects. Using validated PRO measures can guide targeted support and inform the development of screening programmes that minimise psychological adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.